PLM-103 / PeLeMed - LARVOL DELTA

PLM-103: A dual-mechanism YES1/YAP pathway inhibitor exhibiting broad antitumor efficacy and immuno-oncology synergy (AACR 2026) - "The combination of PLM-103 with anti-PD-1 therapy resulted in durable complete responses, underscoring the potent immunomodulatory and immune-potentiating capacity of PLM-103. Collectively, these findings establish PLM-103 as a highly promising next-generation anticancer agent that integrates targeted YES1/YAP pathway inhibition with robust immunomodulatory activity, providing dual and complementary mechanisms capable of addressing a broad range of YAP-driven malignancies."

Clinical • Immuno-oncology • IO biomarker • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Genito-urinary Cancer • Mesothelioma • Oncology • Pancreatic Ductal Adenocarcinoma • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • CCN1 • CD8 • CTGF